Odyssey Therapeutics Seeks $238.3 Million in IPO
Odyssey Therapeutics, a biotech company focused on developing treatments for immune and inflammatory diseases, has announced plans to raise <strong>$238.3 million</strong> through an initial public offering (IPO) in the United States. This announcement comes at a time of increasing investor interest in the biotech industry.